[Federal Register Volume 78, Number 134 (Friday, July 12, 2013)]
[Notices]
[Pages 41952-41953]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2013-16707]


-----------------------------------------------------------------------

INTERNATIONAL TRADE COMMISSION

[Investigation No. 337-TA-857]


Certain Reduced Folate Nutraceutical Products and L-Methylfolate 
Raw Ingredients Used Therein; Commission Determination Not To Review an 
Initial Determination Granting Complainants' Corrected Motion for Leave 
To Amend the Complaint and Notice of Investigation To Add a Complainant 
and Change a Complainant Name

AGENCY: U.S. International Trade Commission.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: Notice is hereby given that the U.S. International Trade 
Commission has determined not to review an initial determination 
(``ID'') (Order No. 12) of the presiding administrative law judge 
granting complainants' corrected motion for leave to amend the 
complaint and notice of investigation to add a complainant and change a 
complainant name.

FOR FURTHER INFORMATION CONTACT: James A. Worth, Office of the General 
Counsel, U.S. International Trade Commission, 500 E Street SW., 
Washington, DC 20436, telephone (202) 205-3065. Copies of non-
confidential documents filed in connection with this investigation are 
or will be available for inspection during official business hours 
(8:45 a.m. to 5:15 p.m.) in the Office of the Secretary, U.S. 
International Trade Commission, 500 E Street SW., Washington, DC 20436, 
telephone (202) 205-2000. General information concerning the Commission 
may also be obtained by accessing its

[[Page 41953]]

Internet server (http://www.usitc.gov). The public record for this 
investigation may be viewed on the Commission's electronic docket 
(EDIS) at http://edis.usitc.gov. Hearing-impaired persons are advised 
that information on this matter can be obtained by contacting the 
Commission's TDD terminal on (202) 205-1810.

SUPPLEMENTARY INFORMATION: The Commission instituted this investigation 
on October 16, 2012, based on a complaint filed on September 10, 2012, 
on behalf of South Alabama Medical Science Foundation of Mobile, 
Alabama (``SASF''); Merck & Cie of Altdorf, Switzerland (``Merck''); 
and Pamlab LLC of Covington, Louisiana (``Pamlab''). 77 FR 63336 
(October 16, 2012). The complaint alleged violations of Section 337 of 
the Tariff Act of 1930, as amended, 19 U.S.C. 1337, by reason of 
infringement of one or more of claims 37, 39, 40, 47, 66, 67, 73, 76, 
78-81, 83, 84, 86-89, 91, 92, 94-97, 99, 100, 110, 111, 113, 117, and 
121 of U.S. Patent No. 5,997,915; claims 22, 26, and 32-38 of U.S. 
Patent No. 6,673,381; claims 1, 4-6, and 15 of U.S. Patent No. 
7,172,778; and claims 1-3, 5, 6, 8, 9, 11-15, and 19-22 of U.S. Patent 
No. 6,011,040. The Commission's notice of investigation named as 
respondents Gnosis SpA of Desio, Italy; Gnosis Bioresearch SA of 
Sant'Antonino, Switzerland; Gnosis USA Inc. of Doylestown, 
Pennsylvania; and Macoven Pharmaceuticals LLC of Magnolia, Texas.
    On December 13, 2012, the Commission issued notice of its 
determination not to review an ID adding Viva Pharmaceuticals LLC as a 
new respondent. On February 4, 2013, the Commission issued notice of 
its determination not to review an ID to identify the new respondent as 
Viva Pharmaceuticals Inc. rather than Viva Pharmaceuticals LLC.
    On May 10, 2013, complainants SASF, Merck, and Pamlab filed an 
unopposed corrected motion for leave to add Nestle Health Science-
Pamlab Inc. (``NHS-Pamlab'') as a complainant and change Pamlab's name 
to Camline LLC. On June 11, 2013, the administrative law judge issued 
an ID (Order No. 12) granting the motion. The administrative law judge 
found good cause shown because NHS-Pamlab has acquired Pamlab and 
Pamlab was renamed following the acquisition. There were no petitions 
for review.
    Having considered the ID and the relevant portions of the record, 
the Commission has determined not to review the subject ID. The 
complaint and notice of investigation are therefore amended to add a 
new complainant NHS-Pamlab and to rename Pamlab as Camline LLC.
    This action is taken under the authority of section 337 of the 
Tariff Act of 1930, as amended (19 U.S.C. 1337), and of section 
210.42(h) of the Commission's Rules of Practice and Procedure (19 CFR 
210.42(h)).

    By order of the Commission.

    Issued: July 8, 2013.
Lisa R. Barton,
Acting Secretary to the Commission.
[FR Doc. 2013-16707 Filed 7-11-13; 8:45 am]
BILLING CODE 7020-02-P